Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sustainable Adherence and Prevention of HIV Drug Resistance in Adolescents (SAPHRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03928834
Recruitment Status : Not yet recruiting
First Posted : April 26, 2019
Last Update Posted : April 26, 2019
Sponsor:
Collaborators:
King's College London
Massachusetts General Hospital
Information provided by (Responsible Party):
University of Zimbabwe

Brief Summary:
The overall goal of this study is to determine if implementation of a package of interventions that includes DBS-based VL monitoring, coupled with an evidence-based intervention to improve ART adherence using cognitive-behavioral principles and genotyping for those with persistent viremia decreases 12-month virologic failure rates among HIV-infected adolescents compared with standard of care (SOC).

Condition or disease Intervention/treatment Phase
Adherence, Medication HIV Resistance Behavioral: Adapted Nzira Itsva Not Applicable

Detailed Description:
In 2014, UNAIDS set ambitious goals to achieve 90% virologic suppression rates among individuals on antiretroviral therapy (ART). In Zimbabwe, this is an ambitious target, particularly among adolescents; less than 5% of human immunodeficiency virus (HIV)-infected individuals received HIV viral load (VL) testing in 2015, as reported by Ministry of Health and Child Care in Zimbabwe and treatment failure rates among adolescents range between 25-37% (Makadzange et al., 2015). Adolescents failing ART also have high rates of drug resistance. Scalable strategies to facilitate improved VL monitoring, adherence support, and genotyping for those with persistent viremia are urgently needed. We have shown that dried blood spot (DBS) samples can be used for routine VL monitoring on existing technologies (Makadzange et al., 2017) We have also adapted an evidence-based, widely-used, cognitive behavioral therapy (CBT) adherence intervention (Life-Steps) for use in Zimbabwe and have identified a low-cost genotyping strategy that can facilitate detection of drug resistance mutations (DRMs) using already existing real-time polymerase chain reaction technology. Our primary study objective is to determine if implementation of a package of care that includes DBS-based VL monitoring, coupled with an evidence-based intervention to improve ART adherence using cognitive-behavioral principles as well as genotyping for individuals with persistent viremia decreases 12-month virologic failure rates among HIV-infected adolescents compared with standard of care (SOC). We hypothesize that our proposed package of care will result in a decrease in virologic failure rates among adolescents. We will also adapt and integrate Nzira Itsva for Adolescents (NI), a cultural adaptation of Life-Steps, into routine care as an adherence support intervention for HIV-infected adolescents, and implement a novel, low-cost genotyping assay using Pan-Degenerate Amplification and Adaptation (PANDAA) of viral ribonucleic acid (RNA) as a point mutation assay for the detection of drug resistance in parallel with Sanger sequencing. Process and cost data will be collected for subsequent cost-analysis. The proposed intervention will be a two-arm, cluster-randomized trial in Mashonaland West and Matabeleland North provinces of Zimbabwe. The units of randomization will be public and largely rural clinics within the provinces, with sites randomized to the intervention or to the SOC. The study is anticipated to show that the use of DBS in routine monitoring of adolescents is feasible, and to show that CBT, if incorporated into routine counselling activities, can complement VL monitoring and genotyping to reduce treatment failure rates and preserve therapeutic options for infected adolescents. The results of this study will have important implications in Zimbabwe and other low-income countries in sub-Saharan Africa with a large proportion of HIV-infected adolescents. The study will include young adolescents aged 10- <14years, as well as older adolescents aged 15-19 years and therefore provide data that will guide implementation of strategies for virologic success in the growing number of perinatally-infected children who are surviving on ART into adolescence, as well as for behaviorally-infected adolescents. The study will be performed within 44 clinics in Matabeleland North and Mashonaland West provinces, and will recruit 828 adolescents. We have assembled a multidisciplinary consortium with the expertise to conduct this study. The consortium includes public health practitioners, a biostatistician, basic scientists with extensive experience in virology and development of novel technologies, HIV clinicians with experience in implementation science, global mental health, and behavioral psychology experts. The consortium will work in partnership with the Ministry of Health (MOH) to implement this protocol and ensure its success.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 828 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Two-arm, cluster-randomized trial

1) clinics that provide the Standard of care (SOC)VL testing and management to adolescents and 2) clinics that provide an enhanced adherence package consisting of VL testing using Dried Blood Spots(DBS), including the Nzira Itsva ( NI) intervention and low-cost genotyping and drug resistance monitoring.

Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Implementing a Sustainable Adherence Intervention and Monitoring Virologic Suppression and Drug Resistance Among HIV-infected Adolescents Receiving Antiretroviral Therapy in Zimbabwe (SAPHRA)
Estimated Study Start Date : August 1, 2019
Estimated Primary Completion Date : September 1, 2021
Estimated Study Completion Date : September 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Adapted Nzira Itsva Intervention
Participants will be attending clinics that provide an enhanced adherence package to the adolescents consisting of viral load (VL) testing using DBS, including the Nzira Itsva(NI) intervention and low-cost genotyping and drug resistance monitoring
Behavioral: Adapted Nzira Itsva
Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.

No Intervention: Standard of Care( SOC)
Participants will be attending clinics that provide the standard of care (SOC) VL testing and management to adolescents



Primary Outcome Measures :
  1. To determine VL suppression rates in adolescents in SOC and intervention arm [ Time Frame: 12 months ]
    Arm-specific VL suppression rates will be estimated by the proportion of adolescents on ART that have a VL less than 1000 copies/mL at 12 months from study enrolment.

  2. To determine the prevalence of Drug Resistance Mutations(DRMs) among adolescents on ART with a VL≥1000 [ Time Frame: 12 months ]
    Prevalence of DRMs within each drug class will be determined: frequency of single-drug class DRMs vs. dual-class DRMs vs. triple-class DRMs. Frequencies will be assessed for clinically-relevant point mutations to national 1st- and 2nd-line ART regimens



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. HIV-positive adolescents aged 10-19 years who know their status
  2. On ART for at least 6 months as per clinic records: the patient will have attended the clinic as shown in clinic records at least once since initiation AND will have re-filled their ART at least once since initiation as shown in clinic records..
  3. Planning to stay in care at that facility for at least 12 months

Exclusion Criteria:

  1. Participant and/or caregiver unable to give consent and assent
  2. Those participants who the healthcare worker considers to be too ill to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03928834


Contacts
Layout table for location contacts
Contact: Chiratidzo E NDHLOVU, MD +263772412701 mascen@mweb.co.zw
Contact: Takudzwa Mtisi +263772636949 takudzwa.mtisi@gmail.com

Locations
Layout table for location information
Zimbabwe
University of Zimbabwe Not yet recruiting
Harare, Zimbabwe, 000
Contact: Chiratidzo E Ndhlovu, MD    +283772412701    mascen@mweb.co.zw   
Contact: Takudzwa Mtisi    +263772636949    takudzwa.mtisi@gmail.com   
Sponsors and Collaborators
University of Zimbabwe
King's College London
Massachusetts General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Chiratidzo E NDHLOVU, MD University of Zimbabwe

Layout table for additonal information
Responsible Party: University of Zimbabwe
ClinicalTrials.gov Identifier: NCT03928834     History of Changes
Other Study ID Numbers: GH002118-01
First Posted: April 26, 2019    Key Record Dates
Last Update Posted: April 26, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Informed Consent Form (ICF)

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Zimbabwe:
adolescence, HIV drug resistance mutations, genotyping, dried blood spots